Since NF‐κB/IL‐6 signaling axis is activated in Covid‐19 and appoints pathogenesis and severity of MM, targeting this axis may reduce the severity of both Covid‐19 and MM. This evidence concerns the gene IL6 and Miyoshi myopathy.